• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Azitra Inc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8/20/25 4:30:38 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    false --12-31 0001701478 0001701478 2025-08-20 2025-08-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    August 20, 2025

    Date of Report (date of earliest event reported)

     

     

     

    AZITRA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41705   46-4478536

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    21 Business Park Drive

    Branford, CT 06405

    (Address of principal executive offices and zip code)

     

    (203) 646-6446

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report.)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol   Name of each exchange on which registered
    Common Stock, par value $0.0001   AZTR   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 3.03 Material Modification to Rights of Security Holders.

     

    To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (the “Current Report”) is incorporated herein by reference.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On August 20, 2025, Azitra, Inc. (the “Company”) filed a certificate of amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effectuate a 1-for-6.66 reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock (“Common Stock”). The Company’s stockholders previously approved the Reverse Stock Split and granted the board of directors the authority to determine the exact split ratio and when to proceed with the Reverse Stock Split at the Company’s special meeting of stockholders held on February 20, 2025.

     

    The Reverse Stock Split will become effective on August 21, 2025 at 12:01 a.m., Eastern Time (the “Effective Time”) and the Common Stock is expected to begin trading on the NYSE American on a Reverse Stock Split-adjusted basis on August 21, 2025 at market open. As of the Effective Time, every 6.66 shares of the Company’s issued and outstanding Common Stock will be combined into one share of Common Stock.

     

    The par value and other terms of the Common Stock will not be affected by the Reverse Stock Split. The Company’s post-Reverse Stock Split Common Stock CUSIP number will be 05479L 302.

     

    No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share of Common Stock will receive a cash payment in lieu thereof at a price equal to (i) the average closing price of the Common Stock for the five trading days immediately preceding August 20, 2025, multiplied by (ii) the number of shares of Common Stock outstanding immediately prior to effectiveness of the Reverse Stock Split that were reclassified into such fractional share pursuant to the Reverse Stock Split.

     

    The foregoing description of the Amendment is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report and is incorporated herein by reference.

     

    Forward-Looking Statements

     

    This Current Report includes forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “will” and “expected”, or the negative of such terms, or other comparable terminology, and include statements about the Reverse Stock Split and the impacts, if any, on the Company’s Common Stock. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due to many factors. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this Current Report, and the Company expressly disclaims any obligation or undertaking to update or revise and forward-looking statement contained herein, or to reflect any change in the Company’s expectations with regard thereto or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent otherwise required by applicable law.

     

    Item 9.01 - Financial Statements and Exhibits

     

    (d): The following exhibits are being filed electronically herewith:

     

    Exhibit No.   Description
    3.1   Certificate of Amendment filed with the Delaware Secretary of State on August 20, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on August 20, 2025.

     

     

    AZITRA, INC.

         
     

    By:

    /s/ Francisco D. Salva
     

    Name:

    Francisco D. Salva
     

    Title:

    Chief Executive Officer

     

     

     

     

     

    Get the next $AZTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

    4 - Azitra, Inc. (0001701478) (Issuer)

    4/1/24 9:51:59 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azitra, Inc. Announces Reverse Stock Split

    Common Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 6.66 pre-split shares. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on August 21, 2025. The Company's common stock will continue to be traded on the NYSE American under the symbol "AZTR" and will begin trading on a split-adjusted basis when the market opens on August 21, 2025. The

    8/11/25 4:15:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome

    Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application siteTrial is 50% enrolled; six patients have received ATR12-351, a live precision dermatology therapeutic candidate Azitra presenting at the 2025 BIO International ConventionBRANFORD, Conn., June 17, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.

    6/17/25 8:02:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Presentation at the 2025 BIO International Convention

    BRANFORD, Conn., June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associ

    6/10/25 8:33:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

    4 - Azitra, Inc. (0001701478) (Issuer)

    4/1/24 9:51:59 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    SEC Filings

    View All

    Azitra Inc filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    8/20/25 4:30:38 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    8/11/25 4:02:29 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Azitra Inc

    10-Q - Azitra, Inc. (0001701478) (Filer)

    8/11/25 4:01:34 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    View All

    Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

    BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

    7/11/23 4:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Financials

    Live finance-specific insights

    View All

    Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

    2/24/25 8:30:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

    11/12/24 5:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

    Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

    8/12/24 6:23:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/6/24 4:35:43 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care